Fig 2: Relationship between GSDMD mRNA expression and disease-specific survival duration in the TCGA glioblastoma cohort. Each point represents an individual patient. Correlation coefficients were calculated using Pearson and Spearman tests. (p-value = 1.2 × 10−13; n = 671 samples).

Fig 3: (A) Representative images of glioma and (B) correlation between serum gasdermin D (GSDMD) level and tumor size in all glioma patients (n = 62). For the correlation analysis between variables, Spearman’s rank-order correlation method was used.

Fig 4: The correlation between serum gasdermin D (GSDMD) level and basic laboratory parameters in all glioma patients (n = 59). For the correlation analysis between variables, Spearman’s rank-order correlation method was used. Abbreviations: PT—prothrombin time; INR—international normalized ratio; APTT—activated partial thromboplastin time; CREA—creatinine; CRP—C-reactive protein; WBCs—white blood cells; RBCs—red blood cells; HGB—hemoglobin; HCT—hematocrit; MCV—mean corpuscular volume; MCHC—mean corpuscular hemoglobin concentration; MCH—mean corpuscular hemoglobin; MPV—mean platelet volume; PLT—platelet; GSDMD—gasdermin D.

Fig 5: Serum levels of GSDMD in controls (CON) and patients with glioma (GLIOMA) depending on glioma grade (A), sex (B), and BMI (C). Data are presented as median (minimum–maximum) (CON, n = 26; GLIOMA, n = 59). * p < 0.05, *** p < 0.001 controls versus patients with glioma by one-way ANOVA test. Abbreviations: CON—controls, GSDMD—gasdermin D, BMI—body mass index.